4/A: CFO Soderquist Boosts Bioxytran Stake via Acquisition & Conversion

Bioxytran CFO Ola Soderquist acquired over 10 million preferred shares as payment for NDPD Pharma and converted preferred stock to common shares.

Summary

• Ola Soderquist, CFO, Director, and 10% owner of Bioxytran, Inc. (BIXT), reported several transactions on October 25, 2024, via an amended Form 4 filing.
• Soderquist acquired 10,069,396 preferred shares at a price of $0.545 per share.
• These preferred shares were issued as payment for the sale of NDPD Pharma to Bioxytran.
• Additionally, Soderquist acquired 100,000 preferred shares at $0.005 per share.
• These 100,000 preferred shares were subsequently exchanged at a 1:5 ratio into 500,000 shares of common stock, acquired at $0.001 per share.
• Following these transactions, Soderquist beneficially owns 13,876,456 preferred shares and 500,000 common shares directly.

Sentiment

Score: 6

Explanation: The acquisition of NDPD Pharma and the increase in insider ownership by a key executive (CFO, Director, 10% Owner) could be viewed positively as a sign of confidence and strategic growth. However, the extremely low per-share prices for some transactions and the unusual future dates for both transaction and signature dates introduce uncertainty.

Positives

• The acquisition of NDPD Pharma by Bioxytran, for which Soderquist received shares, could indicate strategic growth for Bioxytran.
• Soderquist, a key insider (CFO, Director, 10% Owner), increasing their stake in the company through these transactions could be seen as a sign of confidence.

Negatives

• The low price of the common stock ($0.001) and one preferred stock transaction ($0.005) might suggest a low valuation or distressed equity.
• The transaction date of October 25, 2024, and the signature date of November 18, 2025, are in the future, which is highly unusual for a Form 4/A reporting past transactions and could indicate a clerical error in the filing or the provided text.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4/A filing.

Industry Context

This filing primarily details insider transactions and an acquisition payment, offering limited direct insight into broader industry trends. The acquisition of NDPD Pharma by Bioxytran suggests potential expansion or strategic alignment within the biotechnology or pharmaceutical sector, but specific details are not provided.

Comparison to Industry Standards

• This filing is a standard insider transaction report (Form 4/A) and does not contain information suitable for comparison to global benchmarks or specific comparable companies/projects.

Related Party Transactions

• The issuance of 10,069,396 preferred shares to Ola Soderquist as payment for the sale of NDPD Pharma to Bioxytran constitutes a related party transaction, given Soderquist's roles as CFO, Director, and 10% Owner of Bioxytran.

Stakeholder Impact

• Shareholders: The acquisition of NDPD Pharma could potentially enhance Bioxytran's asset base or strategic position, which might benefit shareholders in the long term. Insider share acquisition could signal management confidence.

Key Dates

Recommendation

While the insider acquisition of shares and the company's acquisition of NDPD Pharma could be seen as positive indicators of strategic growth and management confidence, the extremely low per-share prices for some transactions and the unusual future dates listed in the filing introduce significant uncertainty and potential red flags. Investors should hold and await further clarification or more comprehensive financial reporting before making a definitive investment decision.

Keywords

BIOXYTRAN, BIXT, Ola Soderquist, Insider Trading, Form 4/A, Preferred Stock, Common Stock, Stock Conversion, NDPD Pharma, Acquisition, CFO, Director, 10% Owner